Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 14 Gynecologic 12 Thoracic 4 Sarcoma 4 Genitourinary 3 Gastrointestinal 2 Tumor-Agnostic 1 Head & Neck 1 CNS 1

Conditions

Interventions

Surveys and Questionnaires 70 Blood Specimen Collection 48 Radiotherapy 39 Magnetic Resonance Spectroscopy 35 pembrolizumab 31 Gemcitabine 30 Bevacizumab 30 Nivolumab 29 Carboplatin 29 Radiosurgery 27 Standard of Care 26 Oxaliplatin 26 Capecitabine 25 Paclitaxel 24 Interviews as Topic 24 Cisplatin 24 Fluorouracil 23 Erlotinib Hydrochloride 22 Everolimus 19 Irinotecan 18 Trastuzumab 17 Methods 17 Exercise 17 Docetaxel 17 Biopsy 17 Cyclophosphamide 16 Educational Status 15 Sorafenib 14 Ipilimumab 14 Fluorodeoxyglucose F18 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × fluzoparib × Tumor-Agnostic × Clear all

NCT04774406 2023-06-06

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

University Hospital, Caen

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡